Stay updated on NIR178 and PDR001 Combo in Solid Tumors: Clinical Trial

Sign up to get notified when there's something new on the NIR178 and PDR001 Combo in Solid Tumors: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the NIR178 and PDR001 Combo in Solid Tumors: Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 6 to 7, indicating a recent update in the context of Medical and healthcare-related publications and documentation.
    Difference
    0.3%
    Check dated 2024-05-22T07:45:57.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    15 days ago
    Change Detected
    Summary
    The change on the webpage possibly concerns the termination of a Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma sponsored by Novartis Pharmaceuticals.
    Difference
    27%
    Check dated 2024-05-08T22:18:27.000Z thumbnail image
  7. Check
    17 days ago
    Change Detected
    Summary
    The value for Researcher View Res has recently changed to . This change may indicate an update or modification related to medical and healthcare-related publications and documentation.
    Difference
    21%
    Check dated 2024-05-07T12:37:15.000Z thumbnail image
  8. Check
    23 days ago
    Change Detected
    Difference
    3%
    Check dated 2024-04-30T22:19:04.000Z thumbnail image

Stay in the know with updates to NIR178 and PDR001 Combo in Solid Tumors: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the NIR178 and PDR001 Combo in Solid Tumors: Clinical Trial page.